An Empirical Evaluation of Guidelines on Prostate-specific Antigen Velocity in Prostate Cancer DetectionVICKERS, Andrew J; TILL, Cathee; TANGEN, Catherine M et al.Journal of the National Cancer Institute. 2011, Vol 103, Num 6, pp 462-469, issn 0027-8874, 8 p.Article

Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle invasive bladder cancerLERNER, Seth P; TANGEN, Catherine M; SUCHAREW, Heidi et al.Urologic oncology. 2009, Vol 27, Num 2, pp 155-159, issn 1078-1439, 5 p.Article

Phase III prostate cancer prevention trials : Are the costs justified?THOMPSON, Ian M; TANGEN, Catherine M; KLEIN, Eric A et al.Journal of clinical oncology. 2005, Vol 23, Num 32, pp 8161-8164, issn 0732-183X, 4 p.Article

Metastatic carcinoma of the prostate: Identifying prognostic groups using recursive partitioningGLASS, Tracy R; TANGEN, Catherine M; CRAWFORD, E. David et al.The Journal of urology. 2003, Vol 169, Num 1, pp 164-169, issn 0022-5347, 6 p.Article

Non-parametric analysis of covariance for confirmatory randomized clinical trials to evaluate dose-response relationshipsTANGEN, Catherine M; KOCH, Gary G.Statistics in medicine. 2001, Vol 20, Num 17-18, pp 2585-2607, issn 0277-6715Conference Paper

Androgen Receptor CAG Repeat Length and TMPRSS2:ETS Prostate Cancer Risk: Results From the Prostate Cancer Prevention TrialFIGG, William D; CHAU, Cindy H; VAN BOKHOVEN, Adrie et al.Urology (Ridgewood, NJ). 2014, Vol 84, Num 1, pp 127-131, issn 0090-4295, 5 p.Article

Circulating Tumor Cell Counts Are Prognostic of Overall Survival in SWOG S0421: A Phase III Trial of Docetaxel With or Without Atrasentan for Metastatic Castration-Resistant Prostate CancerGOLDKORN, Amir; ELY, Benjamin; MONK, J. Paul et al.Journal of clinical oncology. 2014, Vol 32, Num 11, pp 1136-1142, issn 0732-183X, 7 p.Article

Plasma Vitamin D and Prostate Cancer Risk: Results from the Selenium and Vitamin E Cancer Prevention TrialKRISTAL, Alan R; TILL, Cathee; MINASIAN, Lori M et al.Cancer epidemiology, biomarkers & prevention. 2014, Vol 23, Num 8, pp 1494-1504, issn 1055-9965, 11 p.Article

Serum 25-Hydroxyvitamin D Concentrations and Risk of Prostate Cancer: Results from the Prostate Cancer Prevention TrialSCHENK, Jeannette M; TILL, Cathee A; TANGEN, Catherine M et al.Cancer epidemiology, biomarkers & prevention. 2014, Vol 23, Num 8, pp 1484-1493, issn 1055-9965, 10 p.Article

The prognostic value of hemoglobin change after initiating androgen-deprivation therapy for newly diagnosed metastatic prostate cancer : A miiltivariate analysis of southwest oncology group study 8894BEER, Tomasz M; TANGEN, Catherine M; BLAND, Lisa B et al.Cancer. 2006, Vol 107, Num 3, pp 489-496, issn 0008-543X, 8 p.Article

SWOG-9510: Evaluation of topotecan in hormone refractory prostate cancer: A Southwest Oncology Group StudyKLEIN, Catherine E; TANGEN, Catherine M; BRAUN, Thomas J et al.The Prostate. 2002, Vol 52, Num 4, pp 264-268, issn 0270-4137Article

Association of African-American ethnic background with survival in men with metastatic prostate cancerTHOMPSON, Ian M; TANGEN, Catherine M; TOLCHER, Anthony et al.Journal of the National Cancer Institute. 2001, Vol 93, Num 3, pp 219-225, issn 0027-8874Article

Chronic Inflammation in Benign Prostate Tissue Is Associated with High-Grade Prostate Cancer in the Placebo Arm of the Prostate Cancer Prevention TrialGUREL, Bora; LUCIA, M. Scott; PESKOE, Sarah B et al.Cancer epidemiology, biomarkers & prevention. 2014, Vol 23, Num 5, pp 847-856, issn 1055-9965, 10 p.Article

Long-Term Survival of Participants in the Prostate Cancer Prevention TrialTHOMPSON, Ian M; GOODMAN, Phyllis J; TANGEN, Catherine M et al.The New England journal of medicine. 2013, Vol 369, Num 7, pp 603-610, issn 0028-4793, 8 p.Article

Ten-year Follow-up of Neoadjuvant Therapy with Goserelin Acetate and Flutamide Before Radical Prostatectomy for Clinical T3 and T4 Prostate Cancer: Update on Southwest Oncology Group Study 9109BERGLUND, Ryan K; TANGEN, Catherine M; THOMPSON, Ian M et al.Urology (Ridgewood, NJ). 2012, Vol 79, Num 3, pp 633-637, issn 0090-4295, 5 p.Article

Chemoprevention of Prostate Cancer. CommentaryTHOMPSON, Ian M; TANGEN, Catherine M; GOODMAN, Phyllis J et al.The Journal of urology. 2009, Vol 182, Num 2, pp 499-508, issn 0022-5347, 10 p.Article

Association of body mass index with response and survival in men with metastatic prostate cancer : Southwest oncology group trials 8894 and 9916. CommentaryMONTGOMERY, R. Bruce; GOLDMAN, Bryan; TANGEN, Catherine M et al.The Journal of urology. 2007, Vol 178, Num 5, pp 1946-1951, issn 0022-5347, 6 p.Article

Predominant treatment failure in postprostatectomy patients is local: Analysis of patterns of treatment failure in SWOG 8794SWANSON, Gregory P; HUSSEY, Michael A; TANGEN, Catherine M et al.Journal of clinical oncology. 2007, Vol 25, Num 16, pp 2225-2229, issn 0732-183X, 5 p.Article

Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer : Data from southwest oncology group trial 9346 (INT-0162)HUSSAIN, Maha; TANGEN, Catherine M; MACVICAR, Gary et al.Journal of clinical oncology. 2006, Vol 24, Num 24, pp 3984-3990, issn 0732-183X, 7 p.Article

Associations of demographic and lifestyle characteristics with prostate-specific antigen (PSA) concentration and rate of PSA increaseKRISTAL, Alan R; CHEN CHI; TANGEN, Catherine M et al.Cancer. 2006, Vol 106, Num 2, pp 320-328, issn 0008-543X, 9 p.Article

Do the benefits of finasteride outweigh the risks in the prostate cancer prevention trial? CommentaryGROVER, Steven; LOWENSTEYN, Ilka; HAJEK, David et al.The Journal of urology. 2006, Vol 175, Num 3, pp 934-938, issn 0022-5347, 5 p., 1Article

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancerPETRYLAK, Daniel P; TANGEN, Catherine M; BENSON, Mitchell C et al.The New England journal of medicine. 2004, Vol 351, Num 15, pp 1513-1520, issn 0028-4793, 8 p.Article

Optimizing Bladder Cancer Locoregional Failure Risk Stratification After Radical Cystectomy Using SWOG 8710CHRISTODOULEAS, John P; BAUMANN, Brian C; JIWEI HE et al.Cancer. 2014, Vol 120, Num 8, pp 1272-1280, issn 0008-543X, 9 p.Article

Intermittent versus Continuous Androgen Deprivation in Prostate CancerHUSSAIN, Maha; TANGEN, Catherine M; DAWSON, Nancy Ann et al.The New England journal of medicine. 2013, Vol 368, Num 14, pp 1314-1325, issn 0028-4793, 12 p.Article

Plasma Phospholipid Fatty Acids and Prostate Cancer Risk in the SELECTTrialBRASKY, Theodore M; DARKE, Amy K; KLEIN, Eric A et al.Journal of the National Cancer Institute. 2013, Vol 105, Num 15, pp 1132-1141, issn 0027-8874, 10 p.Article